The kinome 'at large' in cancer

Nature Reviews Cancer

Volumn 16, Issue 2, 2016, Pages 83-98

  Fleuren, Emmy D G ^a   Zhang, Luxi ^b,c   Wu, Jianmin ^d   Daly, Roger J ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; PROTEIN KINASE; RNA; HISTONE ACETYLTRANSFERASE; NEK9 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; TATA BINDING PROTEIN ASSOCIATED FACTOR; TATA-BINDING PROTEIN ASSOCIATED FACTOR 250 KDA; TRANSCRIPTION FACTOR IID;

CANCER GENETICS; CARCINOGENESIS; DRUG TARGETING; FUNCTIONAL GENOMICS; GENOMICS; HEREDITY; HIGH THROUGHPUT SCREENING; HUMAN; KINOME; MASS SPECTROMETRY; MOLECULAR PATHOLOGY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REGULATORY MECHANISM; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PROCEDURES;

GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT SCREENING ASSAYS; HISTONE ACETYLTRANSFERASES; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTEOMICS; TATA-BINDING PROTEIN ASSOCIATED FACTORS; TRANSCRIPTION FACTOR TFIID;

EID: 84956699845     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2015.18     Document Type: Review

References (128)

1. Spector, D. H., Varmus, H. E. & Bishop, J. M. Nucleotide sequences related to the transforming gene of avian sarcoma virus are present in DNA of uninfected vertebrates. Proc. Natl Acad. Sci. USA 75, 4102-4106 (1978).
2. Hunter, T. Treatment for chronic myelogenous leukemia: the long road to imatinib. J. Clin. Invest. 117, 2036-2043 (2007).
3. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
4. Hudis, C. A. Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51 (2007).
5. Futreal, P. A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004).
6. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
7. Kan, Z. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869-873 (2010).
8. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
9. Dees, N. D. et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res. 22, 1589-1598 (2012).
10. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
11. Bolli, N. et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 5, 2997 (2014).
12. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013).
13. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
14. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074 (2013).
15. The Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676-690 (2014).
16. The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014).
17. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014).
18. The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013).
19. Guan, J., Gupta, R. & Filipp, F. V. Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma. Sci. Rep. 5, 7857 (2015).
20. Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215-1228 (2015).
21. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
22. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202-209 (2014).
23. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
24. Tagliabracci, V. S., Pinna, L. A. & Dixon, J. E. Secreted protein kinases. Trends Biochem. Sci. 38, 121-130 (2013).
25. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).
26. Rubio-Perez, C. et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27, 382-396 (2015).
27. Davoli, T. et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell 155, 948-962 (2013).
28. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
29. Yoshihara, K. et al. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene 34, 4845-4854 (2015).
30. Owens, P. et al. Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proc. Natl Acad. Sci. USA 109, 2814-2819 (2012).
31. Togashi, Y. et al. Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. Mol. Cancer 13, 126 (2014).
32. Wang, J. Y. The capable ABL: what is its biological function? Mol. Cell. Biol. 34, 1188-1197 (2014).
33. Wagner, E. F. & Nebreda, A. R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 9, 537-549 (2009).
34. Smith, S. C. et al. A gemcitabine sensitivity screen identifies a role for NEK9 in the replication stress response. Nucleic Acids Res. 42, 11517-11527 (2014).
35. Sonoshita, M. et al. Promotion of colorectal cancer invasion and metastasis through activation of NOTCH-DAB1-ABL-RHOGEF protein TRIO. Cancer Discov. 5, 198-211 (2015).
36. Nakanishi, Y. et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat. Genet. 45, 98-103 (2013).
37. Blazek, D. et al. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 25, 2158-2172 (2011).
38. Ekumi, K. M. et al. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex. Nucleic Acids Res. 43, 2575-2589 (2015).
39. Bhattacharya, S. et al. Structural and functional insight into TAF1-TAF7, a subcomplex of transcription factor II D. Proc. Natl Acad. Sci. USA 111, 9103-9108 (2014).
40. Wu, Y. et al. Phosphorylation of p53 by TAF1 inactivates p53-dependent transcription in the DNA damage response. Mol. Cell 53, 63-74 (2014).
41. Kloet, S. L., Whiting, J. L., Gafken, P., Ranish, J. & Wang, E. H. Phosphorylation-dependent regulation of cyclin D1 and cyclin A gene transcription by TFIID subunits TAF1 and TAF7. Mol. Cell. Biol. 32, 3358-3369 (2012).
42. Tavassoli, P. et al. TAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domains. Mol. Endocrinol. 24, 696-708 (2010).
43. Antal, C. E. et al. Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor. Cell 160, 489-502 (2015).
44. Creixell, P. et al. Kinome-wide decoding of network-attacking mutations rewiring cancer signaling. Cell 163, 202-217 (2015).
45. Cagnol, S. & Rivard, N. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. Oncogene 32, 564-576 (2013).
46. Akbani, R. et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat. Commun. 5, 3887 (2014).
47. Al-Ejeh, F. et al. Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. Oncotarget 5, 3145-3158 (2014).
48. Zhang, B. et al. Proteogenomic characterization of human colon and rectal cancer. Nature 513, 382-387 (2014).
49. Sharma, K. et al. Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep. 8, 1583-1594 (2014).
50. Britton, D. et al. Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS ONE 9, e90948 (2014).
51. Parker, R., Clifton-Bligh, R. & Molloy, M. P. Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition. Mol. Cancer Ther. 13, 1894-1906 (2014).
52. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007).
53. Yoshida, T. et al. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Clin. Cancer Res. 20, 4059-4074 (2014).
54. Bai, Y. et al. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res. 72, 2501-2511 (2012).
55. Hochgrafe, F. et al. Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. Cancer Res. 70, 9391-9401 (2010).
56. Croucher, D. R. et al. Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway. Cancer Res. 73, 1969-1980 (2013).
57. Lee, B. Y. et al. Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer. Mol. Cancer Ther. 13, 190-201 (2014).
58. Kim, W. et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol. Cell 44, 325-340 (2011).
59. Guo, A. et al. Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol. Cell. Proteom. 13, 372-387 (2014).
60. Moritz, A. et al. Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci. Signal. 3, ra64 (2010).
61. Stokes, M. P. et al. Profiling of UV-induced ATM/ATR signaling pathways. Proc. Natl Acad. Sci. USA 104, 19855-19860 (2007).
62. Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044 (2007).
63. Daub, H. et al. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol. Cell 31, 438-448 (2008).
64. Zhang, L. et al. Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling. J. Proteome Res. 12, 3104-3116 (2013).
65. Xiao, Y., Guo, L. & Wang, Y. A targeted quantitative proteomics strategy for global kinome profiling of cancer cells and tissues. Mol. Cell. Proteom. 13, 1065-1075 (2014).
66. Duncan, J. S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307-321 (2012).
67. Stuhlmiller, T. J. et al. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep. 11, 390-404 (2015).
68. Moghaddas Gholami, A. et al. Global proteome analysis of the NCI-60 cell line panel. Cell Rep. 4, 609-620 (2013).
69. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
70. Kopetz, S. et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Oncol. 28 (15-suppl.), 3534 (2010).
71. Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012).
72. Grueneberg, D. A. et al. Kinase requirements in human cells: I. Comparing kinase requirements across various cell types. Proc. Natl Acad. Sci. USA 105, 16472-16477 (2008).
73. Fedorov, O., Muller, S. & Knapp, S. The (un)targeted cancer kinome. Nat. Chem. Biol. 6, 166-169 (2010).
74. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
75. Bajrami, I. et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res. 74, 287-297 (2014).
76. Yaeger, R. et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin. Cancer Res. 21, 1313-1320 (2015).
77. Cheung, H. W. et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl Acad. Sci. USA 108, 12372-12377 (2011).
78. Marcotte, R. et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov. 2, 172-189 (2012).
79. Brough, R. et al. Functional viability profiles of breast cancer. Cancer Discov. 1, 260-273 (2011).
80. Cowley, G. S. et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci. Data 1, 140035 (2014).
81. Lara, R. et al. An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis. Oncogene 30, 3513-3521 (2011).
82. Weissmueller, S. et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell 157, 382-394 (2014).
83. Baratta, M. G. et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc. Natl Acad. Sci. USA 112, 232-237 (2015).
84. Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528 (2011).
85. Chen, S. et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160, 1246-1260 (2015).
86. Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2010).
87. Mann, K. M. et al. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc. Natl Acad. Sci. USA 109, 5934-5941 (2012).
88. Sos, M. L. et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc. Natl Acad. Sci. USA 109, 17034-17039 (2012).
89. Banerji, V. et al. The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. J. Clin. Invest. 122, 935-947 (2012).
90. Gupte, A. et al. Systematic screening identifies dual PI3K and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma. Clin. Cancer Res. 21, 3216-3229 (2015).
91. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
92. Hollestelle, A., Elstrodt, F., Nagel, J. H., Kallemeijn, W. W. & Schutte, M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol. Cancer Res. 5, 195-201 (2007).
93. Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112 (2013).
94. Punnoose, E. A. et al. Evaluation of circulating tumor cells and circulating tumor DNA in nonsmall cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin. Cancer Res. 18, 2391-2401 (2012).
95. Iacovides, D. C. et al. Identification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay. Mol. Cell. Proteom. 12, 3210-3220 (2013).
96. Worboys, J. D., Sinclair, J., Yuan, Y. & Jorgensen, C. Systematic evaluation of quantotypic peptides for targeted analysis of the human kinome. Nat. Methods 11, 1041-1044 (2014).
97. Pe'er, D. & Hacohen, N. Principles and strategies for developing network models in cancer. Cell 144, 864-873 (2011).
98. Zaman, N. et al. Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets. Cell Rep. 5, 216-223 (2013).
99. Hofree, M., Shen, J. P., Carter, H., Gross, A. & Ideker, T. Network-based stratification of tumor mutations. Nat. Methods 10, 1108-1115 (2013).
100. Lee, M. J. et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794 (2012).
101. So, J. et al. Integrative analysis of kinase networks in TRAIL-induced apoptosis provides a source of potential targets for combination therapy. Sci. Signal. 8, rs3 (2015).
102. Chartier, M., Chenard, T., Barker, J. & Najmanovich, R. Kinome Render: a standalone and web-accessible tool to annotate the human protein kinome tree. PeerJ. 1, e126 (2013).
103. Perna, D. et al. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proc. Natl Acad. Sci. USA 112, E536-E545 (2015).
104. Smit, M. A. et al. ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma. Mol. Syst. Biol. 10, 772 (2014).
105. Ahronian, L. G. et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 5, 358-367 (2015).
106. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
107. Van Allen, E. M. et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94-109 (2014).
108. Fedorenko, I. V. et al. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene http://dx.doi.org/10.1038/onc.2015.188 (2015).
109. Paraiso, K. H. et al. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 5, 264-273 (2015).
110. Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
111. Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848 (2009).
112. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
113. Toyoshima, M. et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc. Natl Acad. Sci. USA 109, 9545-9550 (2012).
114. van der Meer, R., Song, H. Y., Park, S. H., Abdulkadir, S. A. & Roh, M. RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition. Clin. Cancer Res. 20, 3211-3221 (2014).
115. Bhola, N. E. et al. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Res. 75, 405-414 (2015).
116. + breast cancer. Cancer Res. 74, 2119-2130 (2014).
117. Mendes-Pereira, A. M., Lord, C. J. & Ashworth, A. NLK is a novel therapeutic target for PTEN deficient tumour cells. PLoS ONE 7, e47249 (2012).
118. -/- cancer cells detected in a pilot synthetic lethal screen. Proc. Natl Acad. Sci. USA 105, 16484-16489 (2008).
119. Baldwin, A. et al. Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. Proc. Natl Acad. Sci. USA 107, 12463-12468 (2010).
120. Mohni, K. N., Kavanaugh, G. M. & Cortez, D. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. Cancer Res. 74, 2835-2845 (2014).
121. Azorsa, D. O. et al. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J. Transl Med. 7, 43 (2009).
122. Tibes, R. et al. RNAi screening of the kinome with cytarabine in leukemias. Blood 119, 2863-2872 (2012).
123. Josse, R. et al. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase I inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 74, 6968-6979 (2014).
124. Possik, P. A. et al. Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition. Cell Rep. 9, 1375-1386 (2014).
125. Sullivan, K. D. et al. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nat. Chem. Biol. 8, 646-654 (2012).
126. Lamba, S. et al. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell Rep. 8, 1475-1483 (2014).
127. Chaudhuri, L. et al. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica 99, 688-696 (2014).
128. Milosevic, N. et al. Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer. Neoplasia 15, 1354-1362 (2013).